Sapropterin Dihydrochloride Powder for Oral Solution Recalled Due to Sub-Potency
Dr. Reddy's Laboratories is recalling 2,402 cartons of Sapropterin Dihydrochloride Powder 100mg due to sub-potency associated with powder discoloration. The affected lot (T2200352) was distributed nationwide.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: FDA Class I classification applies to this recall. Per the severity rubric, FDA Class I recalls are rated minimum Severe (score 4) because the sub-potent medication may fail to provide intended therapeutic effect, potentially causing serious health consequences.
Plain-English summary
Dr. Reddy's Laboratories, Inc. is recalling 2,402 cartons of Sapropterin Dihydrochloride Powder for Oral Solution 100mg (Lot # T2200352, expiration 12/31/2024, NDC 43598-477-30) because of sub-potency concerns. The powder discoloration in the affected lot is associated with decreased drug potency.
When a medication is sub-potent, it means the drug does not contain the full amount of active ingredient specified on the label. This can result in treatment failure if patients do not receive the intended therapeutic dose.
Patients currently taking this medication from the affected lot should contact their healthcare provider or pharmacist immediately to discuss their treatment options. Do not stop taking your medication without consulting your doctor first, as this could affect your health.
The recalled product
- Product
- Sapropterin Dihydrochloride Powder for Oral Solution 100mg, 30 individual packets per carton, Rx Only, Distributor: Dr. Reddy's Laboratories Inc., Princeton, NJ 08540, Made in India, NDC 43598-477-30.
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Category
- Drug
- Hazard
- sub-potency
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # T2200352
- Exp. 12/31/2024
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27